Subject
Editions published in JCO Precision Oncology 200
Too many entities requested (311). Only 200 are displayed.
-
Germline Pathogenic Variants and Genetic Counseling by Ancestry in Patients With Epithelial Ovarian Cancer
-
Circulating T-Cell Repertoires Correlate With the Tumor Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy
-
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype
-
Clinical and Molecular Characterization of <i>POLE</i> Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers
-
Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?
-
Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice
-
Hairy Cell Leukemia Masquerading as CD5+ Lymphoproliferative Disease: The Importance of <i>BRAF</i> V600E Testing in Diagnosis and Treatment
-
Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant <i>POLE/POLD1</i> Colon Cancer
-
Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors
-
Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1
-
Implications of Incidental Germline Findings Identified In the Context of Clinical Whole Exome Sequencing for Guiding Cancer Therapy
-
P2RY8-CRLF2Fusion-Positive Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Response to Novel Therapy
-
Factors Associated with Declining to Participate in a Pediatric Oncology Next Generation Sequencing Study
-
Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
-
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
-
Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair-Deficient Endometrial Cancer
-
CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade
-
Combined CDK4/6 and PD-1 Inhibition in Refractory SMARCA4-Deficient Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
-
Pathogenic Variants in Cancer Predisposition Genes and Prostate Cancer Risk in Men of African Ancestry
-
Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations
-
Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity
-
Cell-free DNA alterations in the AR enhancer and locus predict resistance to AR-directed therapy in patients with metastatic prostate cancer
-
Majority of -Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High
-
Harnessing Clinical Sequencing Data for Survival Stratification of Patients with Metastatic Lung Adenocarcinomas
-
Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease
-
epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer
-
Patients' Medical and Psychosocial Experiences After Detection of a CDH1 Variant With Multigene Panel Testing
-
Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing
-
Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations
-
Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer
-
Discussion of Trial Designs for Biomarker Identification and Validation Through the Use of Case Studies
-
Detection of Three Distinct Clonal Populations Using Circulating Cell Free DNA: A Cautionary Note on the Use of Liquid Biopsy
Subject - wd:Q89051819